Drug-induced liver injury (DILI) is one of the leading causes of the termination of drug development programs. Consequently, identifying the risk of DILI in humans for drug candidates during the early stages of the development process would greatly reduce the drug attrition rate in the pharmaceutical industry but would require the implementation of new research and development strategies. In this regard, several in silico models have been proposed as alternative means in prioritizing drug candidates. Because the accuracy and utility of a predictive model rests largely on how to annotate the potential of a drug to cause DILI in a reliable and consistent way, the Food and Drug Administration-approved drug labeling was given prominence. Out of 387 drugs annotated, 197 drugs were used to develop a quantitative structure-activity relationship (QSAR) model and the model was subsequently challenged by the left of drugs serving as an external validation set with an overall prediction accuracy of 68.9%. The performance of the model was further assessed by the use of 2 additional independent validation sets, and the 3 validation data sets have a total of 483 unique drugs. We observed that the QSAR model's performance varied for drugs with different therapeutic uses; however, it achieved a better estimated accuracy (73.6%) as well as negative predictive value (77.0%) when focusing only on these therapeutic categories with high prediction confidence. Thus, the model's applicability domain was defined. Taken collectively, the developed QSAR model has the potential utility to prioritize compound's risk for DILI in humans, particularly for the high-confidence therapeutic subgroups like analgesics, antibacterial agents, and antihistamines.
The pharmaceutical industry suffers from a decline in the number of new drugs brought to market (Paul et al., 2010; Watkins, 2011) due to about 90% of drug candidates approved for human testing failing in clinical trials (Kola and Landis, 2004) . Efficacy and toxicity are 2 main causes for drug failure (Arrowsmith, 2011a,b) with drug-induced liver injury (DILI) being a principal cause (Ballet, 1997) . Several methodologies are employed to evaluate risk for DILI at the preclinical stage, including in vivo, in vitro, and in silico approaches (Hamburg, 2011; Zhang et al., 2012) . Notably, in silico computational methods like quantitative structure-activity relationship (QSAR) have been shown to be useful for safety screening during the early stages in drug discovery due to their rapid results and the fact that drug substances are unnecessary (Merlot, 2010; Muster et al., 2008; Thomas and Will, 2012) , and physicochemical nature of compounds like lipophilicity has been identified as an important risk factor for DILI when considering together with daily dose (Chen et al., 2013a; Kaplowitz, 2013) .
QSAR models have been widely used for the study of hepatotoxicity (Przybylak and Cronin, 2012 ) but with only a few studies focusing on predicting risk for DILI in humans (Ekins et al., 2010; Greene et al., 2010; Liu et al., 2011; Rodgers et al., 2010) . For example, Greene et al. (2010) reported a QSAR model for human-specific DILI using a knowledgebased expert system named Derek for Windows. Ekins et al. (2010) also reported a DILI QSAR model using a Bayesian approach. Liu et al. (2011) developed a DILI prediction system (DILIps) by modeling 13 side effects that collectively provided an indication for DILI using a QSAR approach. These pioneering works demonstrated the potential utility of QSAR for predicting complex endpoints associated with heterogeneous mechanisms like DILI in humans. The predictive performance of a QSAR model, particularly its performance as assessed by external validation sets containing chemicals unknown to the training model, is the most important consideration for its potential use in decision making (Thomas and Will, 2012) . To date, the predictive performance of most published models for DILI in humans has been unsatisfactory, with accuracies of approximately 60% or less, especially when the models are challenged by external validation sets. Besides the complex molecular events leading to hepatotoxicity, the limited availability of reliable data on human DILI is a formidable barrier for QSAR modeling (Przybylak and Cronin, 2012) .
In this study, we implemented an improved strategy to develop a QSAR model for DILI in humans. Firstly, the model is developed by using the Food and Drug Administration (FDA)-approved drug labeling data (Chen et al., 2011a) . Human hepatotoxicity data are of crucial importance for QSAR modeling development; however, annotating a drug's potential to cause human hepatotoxicity is a huge challenge (Zimmerman, 1999) and requires the assessment of severity, causality, and incidence (Chen et al., 2011a) . Drug labeling is one of the few public data sources capable of addressing all 3 attributes (Willy and Li, 2004) . Drug labels are drafted by manufacturers and approved by the FDA. Drug manufacturers utilize postmarketing case reports in addition to clinical trial data to incorporate adverse drug reactions (ADRs) in different sections of the drug label. The contents of the labels are reviewed by the FDA; consequently, the decision to include or exclude ADRs in the drug label is relatively consistent and stable. Drug label-based DILI annotation might lead to more reproducible and reliable results for the assessment of a drug's risk for DILI in humans.
Secondly, an extensive model validation strategy was applied to ensure the model's performance that was better than chance and sustainable to the challenge by the largest validation sets that have ever been reported. Specifically, the performance of the model was first assessed with cross-validation and permutation tests and then validated using a total of 483 unique drugs from 3 independent data sets. Given the fact that a QSAR model usually predicts better for some categories of chemicals than for others (ie, applicability domain), we further exploited the dependency of the model performance on the therapeutic categories of drugs. Two groups of therapeutic categories were identified, one associating with a "high-confidence" prediction and the other with the "low-confidence" prediction. As a result, the model achieved a high prediction accuracy (ranging from 68% to 82% for 3 validation sets) for the high-confidence category of drugs.
MATeRIAL AnD MeThODS

NCTR Data Sets With DILI Annotation Using the FDA-Approved Drug Labels
The FDA's National Center for Toxicological Research (NCTR) developed a methodology to assess a drug's potential to cause DILI in humans with FDA-approved drug labeling and the method categorized drugs into 3 groups: most-DILI-concern, less-DILI-concern, and no-DILI-concern (Chen et al., 2011a) . A drug was considered as most-DILI-concern (termed as positive hereafter) if it was withdrawn/discontinued from the market, labeled with a Boxed Warning due to a clinical case of DILI or specifically indicated in the Warnings and Precautions section as a high/moderate DILI risk. No-DILI-concern drugs (termed as negatives hereafter) are those whose drug labels contained no precautions regarding DILI. Drugs that did not fall into these 2 categories were labeled as less-DILI-concern. Because the DILI potential of less-DILI-concern drugs is often debatable, drugs falling into this category were not included in the model development.
In our previous study, we established a DILI annotation for 137 positive drugs and 65 negative drugs (Chen et al., 2011a) . In the present study, the same annotation was carried out for additional drugs numbering approximately 200. Altogether, 176 positive and 211 negative drugs were defined. The data set was divided into training and validation sets based on the drugs' PubChem identification (CID). The training set contains 197 drugs with even numbered CID (81 positives and 116 negatives). The validation set (referred as NCTR validation set hereafter) contains 190 drugs with odd numbered CID (95 positive and 95 negative drugs). The drugs in the NCTR training and validation sets are listed in Supplementary Tables S1 and S2, respectively.
Independent Validation Data Sets
In addition to the NCTR validation set mentioned above, 2 additional data sets were included as independent validation data sets to assess the predictive performance of the QSAR model constructed from the training set. None of the drugs in the 3 validation sets were used in the training set.
One data set was originally reported by Greene et al. (called Greene data set hereafter), which divides drugs into 4 DILI risk groups: HH (evidence for hepatotoxicity in humans), NE (no evidence for hepatotoxicity in any species), WE (weak evidence for human hepatotoxicity with < 10 case reports but generally considered to present no liver injury potential in humans), and AH (animal hepatotoxicity observed, not tested in humans) (Greene et al., 2010) . Because the relevance of both WE and AH to human hepatotoxicity is not well established, only HH and NE drugs were used in this study. Of the 627 drugs/compounds in the original report, 328 drugs were selected for external validation after excluding those drugs that overlapped with the training set: 214 HH drugs and 114 NE drugs (Supplementary Table S3 ).
The second data set used for independent validation was reported by Xu et al. (called Xu data set hereafter) and was annotated according to human hepatotoxicity (Xu et al., 2008) . The data set contains 344 drugs/compounds, but only 241 drugs (132 positives and 109 negatives) were used after excluding those whose chemical structures were not available or overlapped with the training set (Supplementary Table S4) .
Notably, the DILI annotations among the approaches of the NCTR, Greene, and Xu data sets are >80% in agreement (Chen et al., 2011a) . In total, there were 483 unique drugs in the 3 validation data sets with only 54 drugs common to all 3 data sets, 131 drugs shared between the Xu and Greene data sets, 31 shared between the NCTR and Xu data sets, and 6 shared between the NCTR and Greene data sets. More information about these validation sets is shown in Supplementary Figure S1 .
QSAR Modeling
The term QSAR as used in the present study is interpreted broadly to include methodologies that predict activity on an ordinal or categorical scale. The reported QSAR model for predicting human-specific DILI was developed using Mold 2 molecular descriptors (Hong et al., 2008) and the Decision Forest (DF) algorithm (Tong et al., 2003) , both of which were developed in-house at the NCTR/FDA. The overall modeling procedure is depicted in Figure 1 and detailed below. Molecular descriptors. Molecular descriptors for drugs were generated using Mold 2 (http://www.fda.gov/ScienceResearch/BioinformaticsTools/ Mold2/default.htm), a free software tool developed at NCTR. Mold 2 calculates molecular descriptors from 2D chemical structures and has been demonstrated to be reliable for developing QSAR models (Hong et al., 2008) . Specifically, 777 Moldconstant value across all drugs and those with less than 5% of drugs having nonzero values. The remaining 584 descriptors were used in modeling.
QSAR model development.
We previously reported an improved supervised machine learning methodology called DF (Tong et al., 2003) . DF employs a consensus modeling technique of combining multiple heterogeneous decision trees to achieve a more accurate predictive model (Chen et al., 2011b) . DF has been employed in the modeling of a variety of biological systems including complex biological endpoints such as predicting estrogen receptor binding activity and classifying prostate cancer samples (Tong et al., 2004a,b) . In the present study, the DF procedure began with 1 tree that was set up with each node containing a minimum of 5 drugs. The process was then repeated for a second tree using the descriptors that were not used by the previous tree. The process was repeated until no trees could be developed using the remaining descriptors. The trees were constructed using a variant of the Classification and Regression Tree method and were pruned based on tree cost complexity (Tong et al., 2003) . The DF algorithm is implemented in a freely available software tool published by the FDA (http://www.fda.gov/ScienceResearch/ BioinformaticsTools/DecisionForest/default.htm).
Cross-validation.
A 10-fold cross-validation was applied to assess the model performance (Tropsha and Golbraikh, 2007) . The data set was randomly split into 10 equal portions tailored to the ratio between the positive and negative drugs. Nine of the 10 portions were used to develop a model, which was then applied to the remaining portions to assess prediction performance. This process was repeated sequentially so that each of the 10 portions was left out once. The prediction results of the 10 cross-validation models were then averaged to measure the performance. The 10-fold cross-validation was repeated 2000 times to achieve a statistically reliable estimation of the model's performance.
Permutation analysis to assess chance correlation. Permutation analysis is a common approach to determine whether a model's performance estimates differ from random chance (Rodgers et al., 2010) . In this study, the class labels (DILI or not) of drugs in the training set were randomly shuffled, whereas the Mold 2 descriptor values (the independent variables) remained unchanged. We generated 2000 permuted data sets, and for each, a QSAR model was developed. The performance of these 2000 models was compared with the QSAR model derived from the training set. A 2-sided paired t test was used to determine the statistical significance of the difference between the training results and permutation analysis.
Identifying the high-confidence therapeutic subgroups. The World Health Organization's (WHO) Anatomical Therapeutic Chemical (ATC) classification system is widely used for defining drug classes. ATC contains 5 levels of classification according to target organs or systems, therapeutic, pharmacological, and chemical properties. The analysis of determining the dependency of the model performance on the therapeutic categories was based on a total of 94 therapeutic subgroups belonging to the second level of ATC classification.
The high-confidence therapeutic subgroups where the model performed better were identified with cross-validation based on the training set. Specifically, prediction accuracies of all subgroups were ranked based on the prediction results from the 2000 runs of 10-fold cross-validation. Only therapeutic subgroups containing at least 3 drugs in the training set were included in the confidence analysis; otherwise, they were termed as "not defined" and were excluded from the confidence analysis. A subgroup was termed as a high-confidence group if it had a higher accuracy than the overall accuracy assessed by the whole training set and termed as a low-confidence one otherwise. A small number of drugs belonged to multiple therapeutic subgroups. Because the assessment was done within therapeutic subgroups rather than across multiple subgroups, these drugs were counted in each of the subgroups in which they appeared. The high-confidence and low-confidence subgroups determined from cross-validation were further assessed by the 3 external validation data sets.
Statistical Analysis
The odds ratio obtained from logistic regression was used to measure the relative risk for DILI in a specific group, and a 2-sided Fisher's exact test was used to examine the statistical significance of the association. The QSAR mod- 
ReSuLTS
A QSAR model using DF and Mold 2 molecular descriptors based on the NCTR training set of 197 drugs annotated by FDAapproved drug labeling was developed. The QSAR model consisted of 6 decision trees using 82 descriptors (Supplementary Figure S2 and Table S5 ). Cross-validation and permutation analysis were performed to demonstrate that the observed predictive performance was not by chance. Three validation data sets with a total of 483 unique drugs were employed to further assess the model's predictive power. We also identified the highconfidence therapeutic subgroups from the ATC Classification System in which the QSAR model performs best.
Development of the QSAR Model
Two thousand repetitions of 10-fold cross-validation were performed based on the training set; the results are summarized in Table 1 . The mean accuracy, sensitivity, and specificity were 69.7% (relative standard deviation [RSD] = 2.9%), 57.8% (RSD = 6.2%), and 77.9% (RSD = 3.0%), respectively.
FIg. 1.
Flowchart of the quantitative structure-activity relationship (QSAR) model construction and validation process in the present study. The Decision Forest (DF) model was developed using molecular descriptors calculated using Mold 2 . Permutation tests were conducted to assess the level of chance correlation of the model. The predictive performance of the QSAR model was assessed using 2000 repetitions of 10-fold cross-validation and external validation of 3 independent data sets. The applicability of the QSAR model was also assessed using the 3 validation data sets.
A permutation analysis was conducted to assess chance correlation of the model. The results of the 2000 cross-validations and 2000 permutations are plotted in Figure 2 . The median accuracy value from the cross-validations was significantly higher than that of the permutations' results (69.7% vs 48.5%, p = 1.57E-12). The permutation analysis demonstrated that the prediction performance of the QSAR model was not due to random chance.
QSAR Model Performance Evaluated by 3 External Validation Sets
The predictive performance of the QSAR model was assessed by 3 validation data sets: the NCTR, Xu, and Greene validation sets. The QSAR model's estimated performance on these data sets is summarized in Table 1 . The prediction accuracy of the NCTR validation data set (68.9%) was slightly higher than that of the other 2 data sets (63.1% for the Xu data set and 61.6% for the Greene data set).
We specifically assessed drugs appearing in more than 1 of the 3 validation sets and compared the QSAR prediction between drugs with consistent and inconsistent DILI annotations across the validation sets. Among the drugs with consistent annotations between the NCTR validation and the Greene data sets, 69.1% (47/68) of the drugs were correctly predicted by the QSAR model compared with only 58.8% (10/17) of those drugs with inconsistent annotations (the accuracies are calculated based on the NCTR annotation). Similar trends were observed in the comparison between the NCTR validation and Xu data sets or between the Greene and Xu data sets.
Furthermore, the positive prediction rates of the QSAR model on drugs with DILI concern in the drug label's Boxed Warning section, Warnings & Precautions section, and Adverse Reactions section were 76.9% (20/26), 59.3% (51/86), and 42.6% (40/94), respectively.
Identification of High-Confidence Therapeutic Subgroups
Two thousand repetitions of cross-validation based on the training set were performed to segregate therapeutic subgroups defined by the second level of ATC in which the QSAR model had a higher or lower accuracy (ie, to identify high-and low-confidence subgroups) than the overall accuracy (69.7%) as shown in Supplementary Figure S3 . The analysis identified 22 therapeutic subgroups applied in the QSAR model as high-confidence (eg, analgesics, antihistamines, antibacterials, antihemorrhagics, corticosteroids, antihypertensives, vasoprotectives, and muscle relaxants) and 18 low-confidence therapeutic subgroups such as psycholeptics, anabolic agents, calcium channel blockers, antivirals, and anesthetics as detailed in Table 2 .
The predictive accuracy in the high-/low-confidence subgroups as assessed by the 3 validation sets individually was plotted in Figure 3 . The QSAR model performed consistently better on drugs in the high-confidence therapeutic subgroups than on drugs in the low-confidence therapeutic subgroups. 
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The average accuracies for the NCTR validation, Greene, and Xu data sets are 81.8%, 68.6%, and 68.3% for high-confidence therapeutic subgroups and 61.3%, 59.6%, and 64.2% for low-confidence subgroups. Supplementary Table S6 lists the performance for each of the high-/low-confidence subgroups in the 3 validation data sets. When we combined the unique drugs with consistent annotations across the 3 validation data sets, the logistic regression modeling estimated an odds ratio for DILI risk of 7.50 for drugs in the high-confidence subgroup versus 1.95 for drugs in the low-confidence subgroup (Table 3) , and the negative predictive value for the high-confidence subgroup was 77.0% versus 46.6% for the low-confidence subgroup.
DISCuSSIOn
In silico testing strategies like QSAR models have become a promising approach for identification of toxic drug candidates in the early stages of drug discovery (Meanwell, 2011);  however, the predictive performance of the currently available QSAR models in predicting DILI risk in humans is poor. Specifically, the low negative predictive values of these models would increase the risk of toxic drug candidates passing this initial screening and proceeding into the development pipeline (Merlot, 2010; Thomas and Will, 2012) . By using a large number of drugs to develop the QSAR model, relying on FDA-approved drug labeling for DILI annotation, and focusing on high-confidence ATC subgroups, we have achieved an improvement in both overall accuracy (73.6% vs 55%-60%) as well as negative predictive value (77.0% vs 42%-45%) (Ekins et al., 2010; Greene et al., 2010) without significantly sacrificing the positive predictive value (69.1% vs 75%-77%).
Notably, the success of in silico methods for prediction of toxicity largely depends on the quality and quantity of the data used for developing predictive models (Przybylak and Cronin, 2012) . The low frequency of DILI in large patient populations together with the lack of robust biomarkers for diagnosis of DILI has posed a challenge to reliably assess DILI in humans . Our annotation based on FDA drug labels has proved to be more reliable and consistent than other DILI annotation methods that have been proposed in the literature (Chen et al., 2011a) . The importance of the quality of annotation is underscored by our observations. For example, the QSAR model predicted best in drugs with Boxed Warning, followed by drugs with DILI concern in the Warnings & Precautions section and the drugs with DILI concern in the Adverse Reactions section. This is likely due to the fact that the more serious regulatory actions require stronger evidence and so will tend to be more accurate assessments of DILI potential.
For a complicated endpoint like DILI, "one-size-fits-all" approaches are not appropriate (Chen et al., 2013b) . In fact, QSAR models have been found to perform better for some chemicals than others (Netzeva et al., 2005; Rusyn et al., 2012) . Because of this, it is important to identify to which domains QSAR models may be most successfully applied. In the present study, we examined the training set using cross-validation of the QSAR model to identify 22 high-confidence and 18 low-confidence therapeutic subgroups. More importantly, the application of the QSAR model to drugs from the 3 independent validation data sets confirmed superior performance in the high-confidence therapeutic subgroups. Some drugs in the high-confidence subgroups are well documented either to cause or not to cause DILI. For example, acetaminophen is predicted as positive by the QSAR model and belongs to a high-confidence therapeutic subgroup (analgesics) as a well-known DILI drug that accounts for almost half of the acute liver failure cases in the United States (Ostapowicz et al., 2002) . Moreover, our QSAR model works well for some therapeutic subgroups that were reported to rarely cause significant liver injury, such as antihistamines (Fontana, 2008) . Thus, understanding a model's applicability domain will enhance the appropriate use of the model. By focusing on those therapeutic subgroups with high confidence, our QSAR model achieves better performance and allows alternative methods to predict DILI to be developed for other therapeutic subgroups. This approach allows us to address the current problem with the application of QSAR modeling to DILI assessment, which is the overall poor predictive performance of the models.
The applicability domain of QSAR has gained increased attention in the area of predictive modeling (Rusyn et al., 2012; Tong et al., 2004a) . We have investigated both major aspects of applicability domains in the present study: chemical structure space and prediction confidence. The predictive performance for DILI drugs is not obviously improved (mostly less than 5% of increase in accuracy as indicated in Supplementary Table S7) . DILI is a complex and multifactorial endpoint. Its prediction in the drug space is not trivial. The simple dichotomy of application domain based on chemical structure space or prediction confidence might oversimplify the complexity. The therapeutic categories represent respective groups of chemicals in the drug space, which seems to be a useful alternative to stratify the drug space to approach complex endpoints in QSAR. Nonetheless, this finding warrant further investigation by either using a larger set of drug data for DILI or examined in other complex endpoints.
The newly developed QSAR model was based on Mold 2 molecular descriptors (which are calculated from the chemical structure) and built using the DF algorithm, both freely available software packages developed in-house. The molecular descriptors used for the developed QSAR model are very diverse (Supplementary Figure S2 and Table S5 ). For example, hydrophilic factor index (D775) from level 3 in tree #4 reflects a compound's lipophilicity and was recently shown to be an important risk factor for DILI (Chen et al., 2013a) . Moreover, some descriptors define the molecular shape (D242) and size (D123), which may affect off-target activities of drug candidates and thereby contribute to risk for DILI (Leeson and Springthorpe, 2007) . Some caveats should be noted in the application of our QSAR model. Firstly, this study is a retrospective analysis based on a survey of ADRs of marketed drugs, which passed extensive safety testing before obtaining market authorization. Thus, additional studies are needed to assess the full potential of the developed QSAR model. Secondly, the QSAR model has established a statistical association between a compound's chemical structure (ie, molecular descriptors) and the potential to cause DILI in humans but does not necessarily indicate any specific mechanistic relationship. Our study demonstrates that it is possible to develop QSAR models that are capable of accurately predicting a drug's DILI risk in humans. By considering high-quality annotations, such as the FDA-approved drug labeling; utilizing powerful chemoinformatic, bioinformatic, and statistical methods; building the model with a large initial set of drugs; validating the model with external data sets; and focusing on therapeutic subgroups where the model performs best, we have been able to mitigate the problem of low accuracy and negative predictive values while maintaining acceptable positive predictive values. The models may be used for a wide range of applications; for one example, they can identify putative DILI liability of drug candidates during the early drug discovery stages, particularly for those falling in high-confidence therapeutic subgroups like analgesics, antibacterials, and antihistamines.
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